The Center for Biosimilars® recaps the top stories for the week of November 4, 2019.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 4, 2019.
Number 5: The biggest cost difference in filgrastim administrations was seen in the commercially insured population after the launch of a biosimilar, according to a new study.
Number 4: The FDA has issued an establishment inspection report for Biocon’s biosimilars facility, and the company says that it plans to launch its trastuzumab biosimilar soon.
Number 3: Samsung Bioepis has entered into a new commercialization agreement with Biogen for 2 ophthalmology biosimilars.
Number 2: Effective January 1, 2020, UnitedHealthcare patients who are receiving the reference epoetin alfa will be required to switch to Pfizer’s biosimilar.
Number 1: At the end of a lengthy regulatory road for Sandoz, the FDA approved the company’s biosimilar pegfilgrastim referencing Neulasta.
Finally, our e-newsletter asked whether you think that enacting legislation to create a CMS star ratings system based on biosimilar availability would help improve biosimilar uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.